Prenetics Global Limited (NASDAQ:PRE) Stock Has Consensus Price Target of $35.67

Prenetics Global Limited (NASDAQ:PRE) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $35.67.

Several research analysts have issued reports on PRE shares. B. Riley Financial started coverage on Prenetics Global in a research note on Thursday, August 27th. They set a “buy” rating and a $37.00 price objective for the company. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Craig Hallum assumed coverage on shares of Prenetics Global in a report on Thursday, September 17th. They issued a “buy” rating and a $40.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Friday, July 17th. Finally, Benchmark increased their target price on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th.

Insider Activity

In other news, CFO Brian J. Rosin bought 5,100 shares of the business’s stock in a transaction dated Tuesday, August 25th. The stock was bought at an average price of $22.80 per share, for a total transaction of $116,280.00. Following the completion of the purchase, the chief financial officer owned 23,100 shares of the company’s stock, valued at approximately $526,680. The trade was a 28.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Danny Sheng Wu Yeung bought 17,181 shares of Prenetics Global stock in a transaction dated Monday, August 24th. The stock was acquired at an average cost of $21.23 per share, for a total transaction of $364,752.63. Following the completion of the acquisition, the chief executive officer directly owned 112,416 shares in the company, valued at $2,386,591.68. This represents a 18.04% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 47,781 shares of company stock worth $999,778 over the last ninety days.

Institutional Investors Weigh In On Prenetics Global

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Operose Advisors LLC bought a new position in shares of Prenetics Global in the second quarter valued at about $129,000. Renaissance Technologies LLC increased its position in Prenetics Global by 85.1% in the 1st quarter. Renaissance Technologies LLC now owns 31,322 shares of the company’s stock valued at $605,000 after acquiring an additional 14,400 shares in the last quarter. State of Wyoming acquired a new stake in Prenetics Global in the 1st quarter valued at about $48,000. Stevens Capital Partners raised its stake in shares of Prenetics Global by 54.6% in the first quarter. Stevens Capital Partners now owns 28,147 shares of the company’s stock worth $544,000 after acquiring an additional 9,940 shares during the last quarter. Finally, Manatuck Hill Partners LLC bought a new position in shares of Prenetics Global in the fourth quarter worth about $170,000. 25.01% of the stock is owned by institutional investors and hedge funds.

Prenetics Global Stock Performance

Shares of Prenetics Global stock opened at $22.97 on Friday. The firm has a market cap of $387.50 million, a P/E ratio of -5.52 and a beta of 0.31. The firm’s 50-day simple moving average is $21.75 and its 200-day simple moving average is $19.89. Prenetics Global has a twelve month low of $11.36 and a twelve month high of $27.24.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative net margin of 47.43% and a negative return on equity of 21.41%. The firm had revenue of $46.49 million during the quarter, compared to analyst estimates of $49.85 million. On average, equities analysts forecast that Prenetics Global will post -1.86 earnings per share for the current fiscal year.

Prenetics Global Company Profile

Prenetics Global Limited is a health sciences and genomics company focused on consumer health, clinical diagnostics and precision oncology. The company develops and commercializes genetic testing and related healthcare solutions intended to help individuals and clinicians better understand disease risk, make informed health decisions and support personalized care.

Prenetics is known for CircleDNA, a consumer genetic testing platform that provides information related to ancestry, wellness, nutrition, lifestyle and selected health risks.